Background. The risk of anal cancer due to high-risk human papillomavirus (HR-HPV) is higher in women living with human immunodeficiency virus (HIV) than in the general population. We present findings of cervical and anal HPV and cytologic tests at baseline in the EVVA cohort study and HPV persistence data 6 months after baseline.
People living with human immunodeficiency virus (HIV) are at increased risk of cancers related to human papillomavirus (HPV), compared with the general population [1] [2] [3] . Mass screening for cervical cancer has made it possible to curb the mortality associated with cervical cancer in all women, regardless of HIV status [4, 5] . The cancer with the next highest attributable fraction due to HPV is anal cancer [6] , and, like cervical cancer, anal cancer has the potential to be prevented. For this reason, considerable research has examined anal HPV infection and anal cancer screening in men living with HIV who have sex with men [7] [8] [9] [10] [11] [12] [13] [14] [15] . In comparison, HPV-related anal disease in women living with HIV has received far less attention, despite the fact that their risk of anal cancer is estimated to be up to 24 times higher than that for HIV-uninfected women [3, 16] .
The EVVA (Evaluation of Human Immunodeficiency Virus, Human Papillomavirus, and Anal Intraepithelial Neoplasia in women) cohort study was created to study the natural history of anal HPV and anal intraepithelial lesions over 2 years in women living with HIV. The objectives of this article are to present the cervical and anal type-specific HPV infection prevalence overall and by place of birth, HPV persistence 6 months after baseline, and results of baseline cytologic testing.
METHODS

Study Design
The EVVA study is a prospective cohort study of women living with HIV in Montreal, Canada. Participants were recruited between January 2012 and July 2015 through 4 outpatient clinics specializing in HIV care in Montreal: McGill University Health Centre (MUHC), Clinique Médicale l' Actuel, Centre Hospitalier de l'Université de Montréal, and Clinique OPUS. Women were invited to participate by their HIV caregiver at a routine clinical visit. If interested, they were referred to MUHC, where all study visits occurred. Adult women living with HIV were eligible if they were born with a cervix and had not had a total hysterectomy. Exclusion criteria were current pregnancy and past history of invasive anal cancer. One participant completed the study despite having had a total hysterectomy, and she only provided anal samples.
The study involved repeated semiannual measurements via questionnaires, chart reviews, cervical cytologic and HPV testing, and anal cytologic and HPV testing over 2 years (5 visits) . A high-resolution anoscopy (HRA) with collection of 2 biopsy specimens was also performed for all participants at the baseline and 2-year visits, unless the participant was pregnant. Additional HRAs were incorporated into the 6-, 12-, or 18-month visits if findings of previous histologic analysis indicated an anal low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL) or if findings of previous anal cytologic testing indicated HSIL. Women with abnormal results of cervical cytologic tests were referred for colposcopy. Those with persistent anal HSIL lesions were offered treatment through regular clinical services provided by the same anoscopists. The research ethics boards of participating institutions approved the study, and all participants provided written informed consent.
Data Collection
Participants completed a detailed self-administered baseline questionnaire at enrollment, a follow-up questionnaire at each subsequent visit, and an acceptability questionnaire at their last visit or at the time of study withdrawal. Information collected included sociodemographic characteristics, history of sexually transmitted infections (STIs) and anal diseases, smoking, injection drug use, sexual activity, HIV history (including treatment) and HPV vaccine history. The follow-up questionnaires contained a reduced set of questions, probing for changes in risk factors or behavior, and verified the consistency of responses given at baseline. The structured questionnaires were modeled on existing questionnaires previously used and validated in epidemiologic studies of anal cancer screening in HIV-positive men who have sex with men [10, 11] and cervical cancer screening in HIV-negative women [17] .
Clinical charts were reviewed for HIV information (date of diagnosis, CD4 + T-cell counts, HIV loads, and antiretroviral therapy history) and HPV-related information (vaccine exposure, past history of HPV-related anogenital diseases, and colposcopy results).
Cervical and Anal Sample Collection and HPV Testing
A trained research nurse collected cervical and anal samples at each study visit. A cytobrush was inserted through a speculum and rotated in the cervical canal to collect cervical cells. A saline-moistened polyethylene terephthalate swab was then inserted 3-5 cm into the anal canal and removed with a twirling motion while applying gentle pressure to the walls of the canal to collect anal epithelial cells. The collected cervical and anal swabs were agitated in 1.5 mL of PreservCyt solution (Hologic), a methanol-based transport medium that preserves the integrity of epithelial cells, and stored at 4°C for processing in batches. Cell suspensions were centrifuged at 13 000 × g for 15 minutes at 22°C. Pellets were suspended in 300 μL of 20 mmol/L Tris buffer (pH 8.3). DNA was purified using a Master-Pure kit (Epicentre) and then tested with a polymerase chain reaction (PCR) assay [18] .
HPV DNA detection and genotyping were performed using the Linear Array HPV genotyping test by Roche Molecular Diagnostics [19] [20] . Because the HPV-52 probe included in this kit cross-reacts with HPV-33, HPV-35, and HPV-58, samples identified as positive with the HPV-52 probe were further tested with a validated real-time PCR assay specific for type 52 [21] . Samples that did not test positive for any of these types were considered negative for HPV. Samples identified as negative for β-globin and HPV were considered inadequate.
Anal and Cervical Cytologic Testing
Anal and cervical cytologic tests were performed at each study visit. Cervical cells were collected through a cervical speculum with a cytobrush and wooden cervical spatula and then transferred onto a glass slide and fixed with a cytospray for conventional cervical Papanicolaou testing. Anal cells were collected with a saline-moistened polyethylene terephthalate swab inserted 3-5 cm into the anal canal and removed with a twirling motion in exactly the same manner as for anal HPV testing. Until 6 September 2013, material collected for anal cytologic testing was transferred to a glass slide and fixed with a conventional cytospray (the first 243 anal specimens collected for cytologic testing, including 119 baseline specimens). Subsequently, liquid-based cytologic testing was used for anal specimens at the MUHC laboratory; these specimens were agitated in vials containing Cytolyte solution. Anal and cervical cells were prepared and examined by cytotechnologists and cytopathologists of the MUHC cytopathology laboratory and classified as normal; atypical squamous cells of undetermined significance (ASCUS); atypical squamous cells, cannot exclude HSIL (ASC-H); LSIL; or HSIL [22, 23] .
Statistical Analysis
The target sample size of 150 participants was determined using a power calculation based on an expected prevalence of 80% for anal HPV and 15%-20% for the 5 most prevalent high-risk HPV (HR-HPV) types, with the goal of obtaining an adequate precision deemed to correspond to the half-width of the 95% confidence intervals (CIs) that did not exceed 6% [24] [25] [26] [27] . Descriptive statistics with 95% CIs were calculated when appropriate to describe baseline characteristics. To reduce the risk of residual disclosure, exact numbers were not reported for certain characteristics when representing <5% of the cohort. HPV prevalence at both cervical and anal sites was stratified by place of birth. HPV genotypes considered to be HR-HPV were as follows: 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68 [28] . For cytologic test results, samples reported as ASC-H were combined with those reported as HSIL. The Fisher exact test was used to compare binomial outcomes between 2 groups, and χ 2 analysis was used to compare binomial outcomes between ≥3 groups. Statistical analyses were performed with Stata software, version 11.2. Figure 1 presents the flow chart of recruitment and retention. Of the 151 participants entering the study, 117 (77.5%) completed the 2-year visit. Baseline characteristics are described in Table 1 . The median age was 45 years (interquartile range [IQR], 39-52 years). Less than a quarter (23%) of participants were born in Canada, 44% in an African country, and 29% in the Caribbean. The median time since HIV diagnosis was 9.6 years (IQR, 5.2-15.2 years). The median current CD4 + T-cell count was 551 cells/mm 3 (IQR, 111-1220 cells/mm 3 ), and 78% had an undetectable HIV load (defined as <40 copies/mL). Fifty percent had a regular sex partner, and 46% reported no vaginal sex in the previous 6 months. Only 27% reported ever experiencing anal sex; among the 41 women who had, the median time since last anal sex was 6 years (IQR, 2-11 years), and <5% had anal sex in the last 6 months, all with only 1 partner. A past history of sexual abuse was disclosed by 45%. Only 7% had received prophylactic HPV vaccination.
RESULTS
Recruitment, Retention, and Baseline Characteristics of the Participants
Cervical and Anal HPV Prevalence
For HPV testing at baseline, 150 cervical and 150 anal samples were adequate for PCR analysis. One participant did not have a cervix and consequently did not provide cervical samples, and 1 anal sample was considered inadequate because it was negative for β-globin. Overall, anal HPV infection was more prevalent (75.3%; 95% CI, 67.6%-82.0%) than cervical HPV infection (50.0%; 95% CI, 41.7%-58.3%), with a median number of 3 (range, 1-16 types) HPV types in the anal canal and 2 (range, 1-10 types) in the cervix. The prevalence of any HR-HPV was 51.3% (95% CI, 43.0%-59.6%) in the anal canal, with a median of 2 types (range, 1-8 types), and 28.7% (95% CI, 21.6%-36.6%) in the cervix, with a median of 1 type (range, 1-5 types).
The type-specific prevalence of HPV is presented by anatomical site in Figure 2 . All types were more frequently detected in the anal canal than in the cervix. The most prevalent HPV types varied by anatomical site. The most common types in the anal canal were HPV-16, HPV-51, HPV-53, HPV-62, and HPV-84, each detected in 13.3%-16.7%. Conversely, the types detected most frequently in the cervix were HPV-54, HPV-61, HPV-62, HPV-81, and HPV-84, each detected in 6.7%-10.0% of participants. The difference between anal and cervical prevalence was statistically significant for HPV-16, HPV-51, and HPV-73, all being more prevalent in the anal canal. Uncertain or preferred not to answer 9 (6.0)
Vaginal sex
Age at 1st experience 18 (16) (17) (18) (19) Male partners in lifetime, no. 
HPV Prevalence, by Place of Birth
Type-specific prevalence of HR-HPV types, stratified by place of birth, is presented in Figure 3 . The 7 participants born in places other than Canada, Africa, or the Caribbean were excluded for this analysis. All anal HR-HPV types were more prevalent in women born in Canada as compared to women born elsewhere. The difference was statistically significant for anal HPV-16 (31.4% among women from Canada, compared with 7.0% among those from the Caribbean and 12.1% among those from Africa; P = .007) and anal HPV-51 (28.6%, compared with 16.3% and 9.1%, respectively; P = .039). The differences were smaller for cervical HR-HPV but still statistically significant for cervical HPV-35 (8.8%, compared with 2.3% and 0%, respectively; P = .039).
The most common cervical HR-HPV types detected were HPV-31, HPV-56, HPV-58, and HPV-68 (each at 4.6% prevalence) in women born in Africa; HPV-58 (11.6%) for women born in the Caribbean; and HPV-35 and HPV-45 (each at 8.8% prevalence) for women born in Canada. Of HR-HPV types at the anal site, HPV-16 was the most common for women born in Canada (31.4%) and Africa (12.1%), and HPV-51 was the most common for women born in the Caribbean (16.3%).
Comparison of HPV Results at Baseline and 6 Months
We compared HPV results in adequate samples obtained at baseline and 6 months from the cervix of 118 participants, and the anal canal of 117 participants. When all HPV types were combined, 42.4% of women (50 of 118) had cervical samples considered positive for HPV at both visits (but not necessarily for the same HPV type), and 40.7% (48 of 118) had cervical samples negative for all HPV types at both visits. When only HR-HPV types were considered, 23.7% (28 of 118) had cervical samples that tested positive for at least 1 HR-HPV type (but not necessarily the same type) at both baseline and 6 months and would have been considered generically positive for HR-HPV at both times. In the anal canal, 70.9% (83 of 117) had anal samples considered positive for HPV at both visits, and 15.4% (18 of 117) had anal samples considered negative for HPV at both visits. When only HR-HPV types were considered, 46.2% (54 of 117) had anal samples that were considered positive for HR-HPV at both visits.
The HPV type-specific results at both baseline and 6 months were then compared to assess whether each type-specific infection detected at baseline was either no longer detected 6 months later (classified as "cleared") or still detected at 6 months (classified as "persistent") or whether a new HPV type was detected at 6 months (classified as "new"). These results are presented by HPV type in Figure 4 , in absolute numbers. For anal HPV infections detected at 6 months, the proportion that were persistent 15 Cervical High-Risk HPV Anal High-Risk HPV Cleared
Samples, no Samples, no Samples that were negative for HPV at 6 months but positive at baseline (those in which type-specific infection cleared) are represented as negative numbers to distinguish them from samples that were positive at 6 months (those in which type-specific infection was persistent or new).
from baseline varied from 57% for HPV-68 (4 of 7) to 93% for HPV-16 (14 of 15).
Cervical and Anal Cytologic Findings
Baseline results of cervical and anal cytologic tests are presented in Figure 5 . At baseline, results of cervical cytologic testing were normal for 75.7% of women (95% CI, 67.9%-82.3%) and revealed ASCUS for 16.2% (95% CI, 10.7%-23.2%), LSIL for 5.4% (95% CI, 2.4%-10.4%), and ASC-H or HSIL for 2.7% (95% CI, .7%-6.8%). Of note, 2 cervical samples were excluded from analysis: 1 was unsatisfactory for cytologic analysis, and 1 was missing. For baseline anal cytologic testing, results were normal for 63.3% (95% CI, 54.7%-71.3%) and revealed ASCUS for 20.9% (95% CI, 14.4%-28.6%), LSIL for 7.9% (95% CI, 4.0%-13.7%), and ASC-H or HSIL for 7.9% (95% CI, 4.0%-13.7%). Eleven anal samples were excluded because they were considered unsatisfactory for cytologic analysis, and 1 was excluded because it was considered inadequate for HPV testing (it was negative for β-globin). Cervical HR-HPV was prevalent among 18.8% of women (21 of 112) with normal cervical cytologic findings, 45.8% (11 of 24) with ASCUS, 75.0% (6 of 8) with LSIL, and 100% (4 of 4) with cervical ASC-H or HSIL. Similarly, anal HR-HPV was prevalent among 38.6% (34 of 88) with normal anal cytologic findings, 79.3% (23 of 29) with ASCUS, 81.8% (9 of 11) with LSIL, and 72.7% (8 of 11) with ASC-H or HSIL.
DISCUSSION
Our study confirmed the high prevalence of anal and cervical HPV infection in women living with HIV, which is higher than prevalence of these infections reported in HIV-negative female populations [29] [30] [31] [32] [33] . Our results also confirmed the previously reported higher prevalence of anal HPV as compared to cervical HPV [25, 26, 29, 34, 35] . A similar study of 311 women living with HIV in France reported a HR-HPV prevalence of 48% in the anal canal (13% of women had HPV-16) and 26% in the cervix (5% had HPV-16), consistent with our findings [29] . Increased HPV persistence is also likely to occur in HIV-positive women, as HIV affects local immunity [36] [37] [38] [39] . The sexual activity reported by our participants is similar to that previously reported for Canadian women living with HIV [40] . Recent studies also reported high rates of anal HPV infection in men or women who do not report receptive anal penetration [41, 42] , supporting the notion that infection may occur through partner-assisted or independent autoinoculation through contact with hands, genitals, or objects. Of note, 45% of women in our cohort stated that they had experienced past sexual abuse. This finding underlines the importance of recognizing and addressing posttraumatic stress disorder and other issues related to sexual and mental health in women living with HIV.
Many participants (35%) were infected with HR-HPV types not covered by available prophylactic vaccines, but only 7% had received an HPV vaccine. This low vaccinated proportion was expected, given that provincial coverage by HPV vaccines among women living with HIV only extends to age 26 years and that both this coverage and school vaccination programs were only implemented in recent years. Furthermore, most women arriving recently from Africa and the Caribbean did not have HPV vaccine coverage or access in their country of birth.
We observed that HPV type-specific distribution varied by place of birth. Many participants came to Canada after traumatizing events, often involving sexual violence in their country of origin, and had little sexual activity since those events. Among such women, the HPV type distribution is therefore likely to reflect the epidemiology in the country of origin, where most sexual contact occurred. The higher prevalence of HPV-16 in the anal canal of women born in Canada is worrisome, as HPV-16 is the predominant type found in anal cancer in the Canadian province of Quebec [43] . The large proportion of participants born outside Canada reflects the Quebec epidemic of women living with HIV. According to the most recent Quebec HIV demographic analysis, 74% of women receiving a new diagnosis of HIV infection were born outside Canada, and <2% were reported as having Aboriginal ethnicity [44] . Our study population is similar to the population of women living with HIV in many other high-resource countries, as suggested by the ethnicities in a similar cohort in France [29] . We observed high rates of HR-HPV persistence at 6 months for anal HPV, especially HPV-16. It is possible that the new HPV types detected at 6 months or the HPV types that appeared to have been cleared were misclassified. However, persistent cases were detected at both visits and were therefore less likely to have been misclassified as persistent; these persistent cases are also the most worrisome, especially for oncogenic types such as HPV-16 [45] . When all HPV types were combined, 71% of participants tested positive for HPV in the anal canal at both baseline and 6 months. This proportion exceeds the 63% persistence previously reported in men and women living with HIV [46] and the 59% reported by other researchers in a population of men who have sex with men (51% for HR-HPV) [47] .
Our rates of abnormal findings of cytologic tests are also similar to those of previous studies [48, 49] . The vast majority (>72%) of abnormal cervical or anal cytologic findings were associated with HR-HPV infection at the same anatomical site. However, more than one third of normal anal cytologic findings were also associated with HR-HPV at the same site. We expected all anal HSIL/ASC-H to be in patients positive for anal HR-HPV, but 2 patients with ASC-H and 1 with HSIL were negative for HR-HPV. An analysis of the correlation between cytologic findings and histologic diagnosis based on analysis of HRA-associated biopsy specimens will follow.
Although modest in size, our cohort study remains one of the largest longitudinal prospective studies of anal cancer screening in women living with HIV that includes HPV testing, cytologic testing, and systematic HRA in all participants. One potential source of bias considered during recruitment was the possibility that women with past HPV-related cervical disease might be more drawn to the study or more likely to be encouraged by their treating physician to participate. Yet, only 6% of our participants had a past history of cervical HSIL; this proportion is what would be expected in a population of women living with HIV in North America [50] .
These results have important implications for anal cancer screening programs. First, the high level of HR-HPV reduces the usefulness of HPV testing as a screening tool. The high number of abnormal anal cytologic findings also indicates that if we were to apply the same criteria as for cervical cytologic testing, 37% of women would require further investigation with HRA. This finding is of major importance for the planning of screening programs, as resources are generally scant in this regard. The important difference in HPV-16 prevalence according to place of birth suggests that women living with HIV may not all carry the same risk of anal cancer and raises the question of whether certain criteria could be used to better target screening.
In conclusion, anal HPV infection is highly prevalent in women living with HIV, despite low levels of sexual activity overall and anal sex in particular, and is more prevalent than cervical HPV. In the EVVA cohort, HPV type-specific distribution varies by place of birth, with anal HPV-16 more prevalent in women born in Canada. Most type-specific anal HR-HPV infections were detected at both baseline and 6 months, and most abnormal cytologic findings were associated with infection by a HR-HPV type at the same anatomical site. We will report on histologic findings from HRA and the acceptability of screening tests, in future publications. As anal cancer incidence continues to rise in women living with HIV [1] , there is a need for ongoing consideration of anal cancer screening, as well as further studies to better understand the impact of the high rates of anal HR-HPV prevalence and persistence in this population. Acknowledgments. We thank the participants, who generously contributed their time and commitment to this study; the referring physicians and clinics; and the members of members of the EVVA study group, whose help and contribution made the realization of this project possible. 
